The Standing Problem: How a Procedural Gap Became Substantive Restriction

The Official Narrative

A federal appeals court has issued a ruling blocking mail-order distribution of mifepristone, the first drug in the two-pill medication abortion regimen. The decision restricts telemedicine abortion services nationwide, requiring patients to obtain the medication in person from certified healthcare providers. The plaintiffs—medical organizations claiming their members suffer indirect harm when treating patients with abortion complications—argue the FDA's expansion of access in recent years violated administrative procedure requirements. The court's order reinstates pre-2021 restrictions while litigation continues.

The framing centers on drug safety and regulatory process: that the FDA moved too quickly, relied on insufficient evidence, and compromised patient welfare by relaxing in-person dispensing requirements during the COVID-19 pandemic and maintaining those changes afterward.

The Constitutional and Procedural Framework

Article III of the Constitution limits federal court jurisdiction to actual "cases" and "controversies," requiring plaintiffs to demonstrate concrete, particularized injury that is fairly traceable to the defendant's conduct and likely to be redressed by judicial relief. This standing doctrine, articulated in Lujan v. Defenders of Wildlife (1992), exists not as a technicality but as a structural separation-of-powers principle: federal courts may not issue advisory opinions or resolve generalized grievances better suited to the political branches.

The Administrative Procedure Act (APA) provides that agency action may be set aside only if "arbitrary, capricious, an abuse of discretion, or otherwise not in accordance with law." Courts apply a highly deferential standard to agency scientific and medical judgments, as established in Chevron U.S.A., Inc. v. Natural Resources Defense Council (1984) and Motor Vehicle Manufacturers Ass'n v. State Farm Mutual (1983). The reviewing court must determine whether the agency "examined the relevant data and articulated a satisfactory explanation for its action including a rational connection between the facts found and the choice made."

The FDA's authority to regulate drug distribution stems from the Federal Food, Drug, and Cosmetic Act, which requires the agency to ensure medications are safe and effective for their intended use. The Risk Evaluation and Mitigation Strategy (REMS) program allows the FDA to impose specific restrictions on distribution when necessary to ensure benefits outweigh risks.

The Gap Between Claim and Record

The structural problem emerges in the standing analysis. The plaintiff organizations claim injury based on their members treating patients with abortion complications—but this requires a chain of speculation: that the FDA's mail-order allowance leads to increased medication abortion use, that this increase produces more complications (rather than simply shifting from surgical to medication methods), that these complications specifically reach the plaintiff doctors rather than other providers, and that the complications result from mail-order distribution rather than abortion itself.

Each link represents a supposition. The plaintiffs have not demonstrated that mail-order mifepristone produces higher complication rates than in-person dispensing—the clinical evidence shows mifepristone abortion carries less than a 0.4% major complication rate regardless of dispensing method. They have not shown their members would not treat abortion complications if the distribution method changed. Most critically, they assert a "conscience injury" from being required to provide emergency care that completes an abortion process they oppose—but conscience objections do not constitute Article III injury where federal law already requires emergency medical care regardless of the treatment's relationship to elective procedures.

The traditional standing framework would require dismissal: the plaintiffs seek to litigate the rights of third parties (pregnant patients) to make medical decisions, based on generalized objections to abortion rather than concrete institutional harm. Yet the appeals court proceeded to the merits and issued a nationwide injunction.

What the Gap Reveals

The absence of rigorous standing analysis reveals a structural choice: treating a policy disagreement as if it were a justiciable case. The FDA conducted multiple reviews of mifepristone safety data spanning two decades and determined in-person dispensing requirements no longer served safety purposes that could not be met through other REMS elements. The agency documented its reasoning across hundreds of pages of analysis, including international evidence from healthcare systems with more permissive distribution rules and comparable or better safety outcomes.

The court's decision to impose nationwide relief—rather than plaintiff-specific protection—converts the judiciary into a national pharmacy board, displacing agency expertise with judicial policy preference. This is the mechanism problem: not whether mifepristone should be available by mail, but whether general objections to a medical procedure suffice to create federal court jurisdiction over national drug policy.

The procedural irregularity becomes substantive restriction. By accepting standing based on ideological opposition rather than demonstrated harm, the court creates a template for any membership organization to challenge any FDA drug approval its members morally oppose, provided they might someday treat a patient who used that drug.

The Accountability Mechanism

The Supreme Court addressed precisely this standing theory in Food and Drug Administration v. Alliance for Hippocratic Medicine (2024), unanimously holding that the plaintiff organizations lacked standing to challenge mifepristone's approval. Justice Kavanaugh's opinion emphasized that federal courts are "not the proper forum" for policy disagreements with agency decisions when plaintiffs cannot show concrete injury.

The structural remedy exists: reversal on standing grounds, requiring dismissal without reaching the merits. The alternative—allowing ideological organizations to manufacture jurisdiction through speculative injury chains—transforms judicial review into a roving commission to second-guess technical agency determinations based on who can construct the most sympathetic narrative of indirect harm.

The question is not whether the FDA's decision was wise. The question is whether this plaintiff, claiming this injury, in this procedural posture, can invoke federal judicial power to override it. The constitutional answer has been settled for decades. The gap between that answer and this ruling reflects either unfamiliarity with standing doctrine or willingness to ignore it when substantive preferences align.